LIVIVO - Search results -

Search results

Result 1 - 10 of total 27

Search options

Article ; Conference proceedings: Techniques for sample processing and super-resolution imaging for investigating neuronal and muscular samples

Rizzoli, S

2019 Volume 38, Issue 05

Event/congress	24. Kongress des Medizinisch-Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke (DGM) e.V., Göttingen, 2019-05-09
Language	English
Publishing date	2019-05-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article ; Conference proceedings
ZDB-ID	2223503-6
ISSN	2567-5788 ; 0722-1541
ISSN (online)	2567-5788
ISSN	0722-1541
DOI	10.1055/s-0039-1684945
Database	Thieme publisher's database

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.

Poletti, V / Vancheri, C / Albera, C / Harari, S / Pesci, A / Metella, R R / Campolo, B / Crespi, G / Rizzoli, S

Respiratory research

2021 Volume 22, Issue 1, Page(s) 66

Abstract: Background: FIBRONET was an observational, multicentre, prospective cohort study investigating the baseline characteristics, clinical course of disease and use of antifibrotic treatment in Italian patients with idiopathic pulmonary fibrosis (IPF).: ... ...

Abstract	Background: FIBRONET was an observational, multicentre, prospective cohort study investigating the baseline characteristics, clinical course of disease and use of antifibrotic treatment in Italian patients with idiopathic pulmonary fibrosis (IPF). Methods: Patients aged ≥ 40 years diagnosed with IPF within the previous 3 months at 20 Italian centres were consecutively enrolled and followed up for 12 months, with evaluations at 3, 6, 9 and 12 months. The primary objective was to describe the clinical course of IPF over 12 months of follow-up, including changes in lung function measured by % predicted forced vital capacity (FVC% predicted). Results: 209 patients (82.3% male, mean age 69.54 ± 7.43 years) were enrolled. Mean FVC% predicted was relatively preserved at baseline (80.01%). The mean time between IPF diagnosis and initiation of antifibrotic therapy was 6.38 weeks; 72.3% of patients received antifibrotic therapy within the first 3 months of follow-up, and 83.9% within 12 months of follow-up. Mean FVC% predicted was 80.0% at baseline and 82.2% at 12 months, and 47.4% of patients remained stable (i.e. had no disease progression) in terms of FVC% predicted during the study. Conclusions: FIBRONET is the first prospective, real-life, observational study of patients with IPF in Italy. The short time between diagnosis and initiation of antifibrotic therapy, and the stable lung function between baseline and 12 months, suggest that early diagnosis and prompt initiation of antifibrotic therapy may preserve lung function in patients with IPF. Trial registration: NCT02803580.
MeSH term(s)	Aged ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Idiopathic Pulmonary Fibrosis/physiopathology ; Male ; Prognosis ; Prospective Studies ; Time Factors ; Vital Capacity/physiology
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal
Language	English
Publishing date	2021-02-24
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	2041675-1
ISSN	1465-993X ; 1465-9921
ISSN (online)	1465-993X
ISSN	1465-9921
DOI	10.1186/s12931-021-01643-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus.

Curto, Yasmina / Carceller, Héctor / Klimczak, Patrycja / Perez-Rando, Marta / Wang, Qing / Grewe, Katharina / Kawaguchi, Riki / Rizzoli, Silvio / Geschwind, Daniel / Nave, Klaus-Armin / Teruel-Marti, Vicent / Singh, Manvendra / Ehrenreich, Hannelore / Nácher, Juan

Molecular psychiatry

2024

Abstract: Severe psychiatric illnesses, for instance schizophrenia, and affective diseases or autism spectrum disorders, have been associated with cognitive impairment and perturbed excitatory-inhibitory balance in the brain. Effects in juvenile mice can elucidate ...

Abstract	Severe psychiatric illnesses, for instance schizophrenia, and affective diseases or autism spectrum disorders, have been associated with cognitive impairment and perturbed excitatory-inhibitory balance in the brain. Effects in juvenile mice can elucidate how erythropoietin (EPO) might aid in rectifying hippocampal transcriptional networks and synaptic structures of pyramidal lineages, conceivably explaining mitigation of neuropsychiatric diseases. An imminent conundrum is how EPO restores synapses by involving interneurons. By analyzing ~12,000 single-nuclei transcriptomic data, we generated a comprehensive molecular atlas of hippocampal interneurons, resolved into 15 interneuron subtypes. Next, we studied molecular alterations upon recombinant human (rh)EPO and saw that gene expression changes relate to synaptic structure, trans-synaptic signaling and intracellular catabolic pathways. Putative ligand-receptor interactions between pyramidal and inhibitory neurons, regulating synaptogenesis, are altered upon rhEPO. An array of in/ex vivo experiments confirms that specific interneuronal populations exhibit reduced dendritic complexity, synaptic connectivity, and changes in plasticity-related molecules. Metabolism and inhibitory potential of interneuron subgroups are compromised, leading to greater excitability of pyramidal neurons. To conclude, improvement by rhEPO of neuropsychiatric phenotypes may partly owe to restrictive control over interneurons, facilitating re-connectivity and synapse development.
Language	English
Publishing date	2024-04-15
Publishing country	England
Document type	Journal Article
ZDB-ID	1330655-8
ISSN	1476-5578 ; 1359-4184
ISSN (online)	1476-5578
ISSN	1359-4184
DOI	10.1038/s41380-024-02528-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4812: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study.

Antonelli Incalzi, Raffaele / Canonica, Giorgio Walter / Scichilone, Nicola / Rizzoli, Sara / Simoni, Lucia / Blasi, Francesco

PloS one

2019 Volume 14, Issue 9, Page(s) e0221889

Abstract: Background: This paper is aimed to (i) develop an innovative classification of COPD, multi-dimensional phenotype, based on a multidimensional assessment; (ii) describe the identified multi-dimensional phenotypes.: Methods: An exploratory factor ... ...

Abstract	Background: This paper is aimed to (i) develop an innovative classification of COPD, multi-dimensional phenotype, based on a multidimensional assessment; (ii) describe the identified multi-dimensional phenotypes. Methods: An exploratory factor analysis to identify the main classificatory variables and, then, a cluster analysis based on these variables were run to classify the COPD-diagnosed 514 patients enrolled in the STORICO (trial registration number: NCT03105999) study into multi-dimensional phenotypes. Results: The circadian rhythm of symptoms and health-related quality of life, but neither comorbidity nor respiratory function, qualified as primary classificatory variables. Five multidimensional phenotypes were identified: the MILD COPD characterized by no night-time symptoms and the best health status in terms of quality of life, quality of sleep, level of depression and anxiety, the MILD EMPHYSEMATOUS with prevalent dyspnea in the early-morning and day-time, the SEVERE BRONCHITIC with nocturnal and diurnal cough and phlegm, the SEVERE EMPHYSEMATOUS with nocturnal and diurnal dyspnea and the SEVERE MIXED COPD distinguished by higher frequency of symptoms during 24h and worst quality of life, of sleep and highest levels of depression and anxiety. Conclusions: Our results showed that properly collected respiratory symptoms play a primary classificatory role of COPD patients. The longitudinal observation will disclose the discriminative and prognostic potential of the proposed multidimensional phenotype. Trial registration: Trial registration number: NCT03105999, date of registration: 10th April 2017.
MeSH term(s)	Aged ; Aged, 80 and over ; Anxiety/epidemiology ; Circadian Rhythm ; Cluster Analysis ; Cohort Studies ; Comorbidity ; Cough/physiopathology ; Depression/epidemiology ; Dyspnea/physiopathology ; Factor Analysis, Statistical ; Female ; Humans ; Italy ; Male ; Memory, Episodic ; Middle Aged ; Phenotype ; Pulmonary Disease, Chronic Obstructive/classification ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quality of Life ; Sleep/physiology
Language	English
Publishing date	2019-09-13
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0221889
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A Gender Medicine Post-Hoc Analysis: Background and Methods of the Metagem Project.

Simoni, L / Colombo, D / Bellia, G / Vassellatti, D / Zagni, E / Rizzoli, S / Sgarbi, S

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

2014 Volume 17, Issue 7, Page(s) A406

Language	English
Publishing date	2014-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	1471745-1
ISSN	1524-4733 ; 1098-3015
ISSN (online)	1524-4733
ISSN	1098-3015
DOI	10.1016/j.jval.2014.08.945
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5904: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A gender-medicine post hoc analysis (MetaGeM) project to test sex differences in previous observational studies in different diseases

Colombo D / Bellia G / Vassellatti D / Zagni E / Sgarbi S / Rizzoli S

Open Access Journal of Clinical Trials, Vol 2014, Iss default, Pp 111-

methodology

2014 Volume 116

Abstract: Delia Colombo,1Gilberto Bellia,1Donatella Vassellatti,1Emanuela Zagni,1Simona Sgarbi,2Sara Rizzoli21Novartis Farma, Origgio, 2MediData, Modena, ltalyAbstract: Only recently has medical research begun to understand the importance of taking sex into ... ...

Abstract	Delia Colombo,1Gilberto Bellia,1Donatella Vassellatti,1Emanuela Zagni,1Simona Sgarbi,2Sara Rizzoli21Novartis Farma, Origgio, 2MediData, Modena, ltalyAbstract: Only recently has medical research begun to understand the importance of taking sex into account, recognizing that symptoms and responses to medical treatment may be very different between males and females. However, the analyses provided by the pharmaceutical industry to regulatory authorities often do not present safety and efficacy data by sex. Novartis has started a gender-medicine project called MetaGeM, which includes nine observational studies sponsored by Novartis Farma, Italy; conducted in Italy between 2002 and 2013 in a range of different clinical areas. The MetaGeM project aims to analyze and describe by means of post hoc analyses and meta-analyses, clinical outcomes, therapeutic approaches, and safety data of these studies, by sex: PSYCHAE; GENDER ATTENTION in psoriasis; Synergy in psoriatic arthritis; ICEBERG in HBsAg carriers; SURF and CETRA in liver- and renal transplanted patients, respectively; DEEP in Parkinson's disease; and EVOLUTION and AXEPT in Alzheimer's disease. The present paper describes the methodology of the MetaGeM project.Keywords: gender-medicine, MetaGeM project, methodology
Keywords	Medicine ; R
Subject code	150
Language	English
Publishing date	2014-10-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Gender differences in the adverse events' profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis.

Colombo, Delia / Zagni, Emanuela / Nica, Mihaela / Rizzoli, Sara / Ori, Alessandra / Bellia, Gilberto

Drug design, development and therapy

2016 Volume 10, Page(s) 2917–2927

Abstract: Background: MetaGeM is a wide gender-medicine project comprising post hoc and meta-analyses by gender of clinical outcomes, therapeutic approaches, and safety data from previously conducted observational studies to explore possible gender differences in ...

Abstract	Background: MetaGeM is a wide gender-medicine project comprising post hoc and meta-analyses by gender of clinical outcomes, therapeutic approaches, and safety data from previously conducted observational studies to explore possible gender differences in real-life clinical settings. We report the results of the safety meta-analysis of seven MetaGeM studies, evaluating gender differences in adverse event (AE) incidence and severity. Methods: Data were collected between February 2002 and July 2013. Male and female patients were compared for the main safety variables, using Student's Results: In total, 4,870 patients (46% females, 54% males) were included in the analysis; age was higher for females (mean ± standard deviation 61.2±18.3 years) than males (56.3±16.6 years). Overall, 264 AEs were reported (59.1% in males). There were no significant gender differences in the percentage of patients with at least one AE: 3.0% for females versus 3.9% for males, Conclusion: This safety analysis on a large sample of almost 5,000 patients with different diseases and treated with a wide range of different drugs provides a useful overview on possible gender differences in drug tolerability, which may be helpful in more accurately designing future clinical trials from a gender-specific perspective.
MeSH term(s)	Female ; Gender Identity ; Humans ; Incidence ; Male ; Network Meta-Analysis
Language	English
Publishing date	2016
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2451346-5
ISSN	1177-8881 ; 1177-8881
ISSN (online)	1177-8881
ISSN	1177-8881
DOI	10.2147/DDDT.S97088
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.

Comi, Giancarlo / Pozzilli, Carlo / Morra, Vincenzo Brescia / Bertolotto, Antonio / Sangalli, Francesca / Prosperini, Luca / Carotenuto, Antonio / Iaffaldano, Pietro / Capobianco, Marco / Colombo, Delia / Nica, Mihaela / Rizzoli, Sara / Trojano, Maria

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

2020 Volume 41, Issue 10, Page(s) 2843–2851

Abstract: Background: Fingolimod is the first oral agent approved for treatment of relapsing-remitting multiple sclerosis (RRMS). We aimed to evaluate fingolimod effectiveness in a real-world sample of RRMS patients.: Methods: A retrospective, multicentre ... ...

Abstract	Background: Fingolimod is the first oral agent approved for treatment of relapsing-remitting multiple sclerosis (RRMS). We aimed to evaluate fingolimod effectiveness in a real-world sample of RRMS patients. Methods: A retrospective, multicentre study in patients treated with fingolimod, whom clinical and radiological data were collected in the 2 years preceding and following the initiation of fingolimod. Results: Out of 414 patients, 56.8% received prior first-line injectable disease-modifying therapies, 25.4% were previously treated with natalizumab, 1.2% with immunosuppressant agents, and 16.7% were treatment naive. The annualized relapse rate decreased by 65% in the first year and by 70% after two years of treatment. Age ≤ 40 years, ≥ 1 relapse in the 24 months before fingolimod initiation and previous treatment with natalizumab were risk factors for relapses. Overall, 67.9% patients had no evidence of disease activity (NEDA-3) after 1 year and 54.6% after 2 years of treatment. A higher proportion of naïve (81.2% in 1 year and 66.7% after 2 years) or first-line injected patients (70.2% and 56.6%) achieved NEDA-3 than those previously treated with natalizumab (54.3% and 42.9%). Conclusions: Fingolimod appeared to be effective in naive patients and after first-line treatment failure in reducing risk of relapse and disease activity throughout the 2-year follow-up.
MeSH term(s)	Adult ; Fingolimod Hydrochloride/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Italy ; Multiple Sclerosis ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Natalizumab/therapeutic use ; Retrospective Studies
Chemical Substances	Immunosuppressive Agents ; Natalizumab ; Fingolimod Hydrochloride (G926EC510T)
Language	English
Publishing date	2020-04-21
Publishing country	Italy
Document type	Journal Article ; Multicenter Study
ZDB-ID	2016546-8
ISSN	1590-3478 ; 1590-1874
ISSN (online)	1590-3478
ISSN	1590-1874
DOI	10.1007/s10072-020-04380-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1877: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Brain erythropoietin fine-tunes a counterbalance between neurodifferentiation and microglia in the adult hippocampus.

Fernandez Garcia-Agudo, Laura / Steixner-Kumar, Agnes A / Curto, Yasmina / Barnkothe, Nadine / Hassouna, Imam / Jähne, Sebastian / Butt, Umer Javed / Grewe, Katharina / Weber, Martin S / Green, Kim / Rizzoli, Silvio / Nacher, Juan / Nave, Klaus-Armin / Ehrenreich, Hannelore

Cell reports

2021 Volume 36, Issue 8, Page(s) 109548

Abstract: In adult cornu ammonis hippocampi, erythropoietin (EPO) expression drives the differentiation of new neurons, independent of DNA synthesis, and increases dendritic spine density. This substantial brain hardware upgrade is part of a regulatory circle: ... ...

Abstract	In adult cornu ammonis hippocampi, erythropoietin (EPO) expression drives the differentiation of new neurons, independent of DNA synthesis, and increases dendritic spine density. This substantial brain hardware upgrade is part of a regulatory circle: during motor-cognitive challenge, neurons experience "functional" hypoxia, triggering neuronal EPO production, which in turn promotes improved performance. Here, we show an unexpected involvement of resident microglia. During EPO upregulation and stimulated neurodifferentiation, either by functional or inspiratory hypoxia, microglia numbers decrease. Treating mice with recombinant human (rh)EPO or exposure to hypoxia recapitulates these changes and reveals the involvement of neuronally expressed IL-34 and microglial CSF1R. Surprisingly, EPO affects microglia in phases, initially by inducing apoptosis, later by reducing proliferation, and overall dampens microglia activity and metabolism, as verified by selective genetic targeting of either the microglial or pyramidal neuronal EPO receptor. We suggest that during accelerating neuronal differentiation, EPO acts as regulator of the CSF1R-dependent microglia.
MeSH term(s)	Animals ; Cell Differentiation/drug effects ; Cell Differentiation/genetics ; Erythropoietin/pharmacology ; Hippocampus/metabolism ; Hypoxia, Brain/drug therapy ; Hypoxia, Brain/metabolism ; Mice ; Mice, Transgenic ; Microglia/metabolism ; Neurogenesis/drug effects ; Pyramidal Cells/metabolism
Chemical Substances	EPO protein, human ; Erythropoietin (11096-26-7)
Language	English
Publishing date	2021-08-24
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2649101-1
ISSN	2211-1247 ; 2211-1247
ISSN (online)	2211-1247
ISSN	2211-1247
DOI	10.1016/j.celrep.2021.109548
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A

Colombo, Delia / Frassi, Micol / Mariano, Giuseppa Pagano / Fusaro, Enrico / Lomater, Claudia / Medico, Patrizia Del / Iannone, Florenzo / Foti, Rosario / Limonta, Massimiliano / Marchesoni, Antonio / Raffeiner, Bernd / Viapiana, Ombretta / Di Carlo, Marco / Grembiale, Rosa Daniela / Guggino, Giuliana / Faggioli, Paola / Tirri, Enrico / Perricone, Roberto / Puttini, Pier Carlo Sarzi /

Vita, Salvatore De / Conti, Fabrizio / Rizzoli, Sara / Roncari, Barbara / Fiocchi, Martina / Orsenigo, Roberto / Zagni, Emanuela

Women's health reports (New Rochelle, N.Y.)

2022 Volume 3, Issue 1, Page(s) 162–171

Abstract: Background: ...

Abstract	Background:
Language	English
Publishing date	2022-02-02
Publishing country	United States
Document type	Journal Article
ISSN	2688-4844
ISSN (online)	2688-4844
DOI	10.1089/whr.2021.0063
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED